The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

In adults with cystic fibrosis, gastrointestinal symptoms initially improve with ETI but most do not consistently improve with longer-term use.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Any disease can cause problems in other parts of your body. Your doctor will call these complications. Myelofibrosis is no exception. There’s no guarantee you’ll have other problems.

Stalled microbiomes: Cystic fibrosis disrupts early gut development in infants. ScienceDaily . Retrieved March 3, 2025 from www.sciencedaily.com / releases / 2025 / 02 / 250213143915.htm ...

Macrophage-to-myofibroblast transition (MMT) contributes to CaOx-induced fibrosis in nephrocalcinosis. EZH2 is the critical regulator that promotes kidney fibrosis by meditating MMT via the DUSP23 ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team of Columbia and UCSD researchers may have found a clever solution that ...

Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that affects alveoli elasticity, which leading to higher rates of hospitalization and mortality worldwide.